 |
|
April 21
2004
Non Client
|
E M P I R E
R E L A T I O N S
G R O U P
P R E S E N T S T H E
|
 |
Gold Star Report
|
|
|
Accelr8 Technology Corporation
|
|
Overview
Technologies used in the understanding of human genomics and proteomics are expediting research and development pathways for new targets of vaccines, therapeutics and diagnostic candidates. As a consequence, there is a growing amount of new molecular entities being developed and new targets being identified as a result of powerful new technologies to target these pathways.
Proteomics is an emerging field that holds great promise to greatly improve our understanding of cellular function. However, making protein micro-arrays poses a different problem than the widely available DNA arrays. Researchers must first address the inherent nature of proteins to become denatured by surface tension. Researchers must also address the problem of finding antibodies that are specific enough to the target protein. Although it is the goal of proteomics to identify and quantify all the proteins present in a cell, these vast amounts of data can not be transformed into clinically useful analytical assays without vast improvements in surface chemistry.
Breakthroughs in science, such as Accelr8's proprietary surface chemistry platform, have allowed us to increase the average lifespan, defeat diseases, and improve the quality of life dramatically. Every aspect of our lives has been in some way touched, whether through immunizations, lower risk surgery or just the daily vitamin. Those companies that have and continue to seek faster and more economical ways to reach the next medical breakthrough are at the forefront of the most advanced science. This GoldStar Report™ will highlight Accelr8 Technology Corporation, a company that is providing a new technology platform that can potentially provide tools of paramount importance for the next major medical breakthrough.
While Accelr8 Technology Corporation is relatively new in the micro-array industry, the company has been operating a profitable legacy migration software business since 1987. Today, the Company is focused on the development and marketing of a proprietary surface chemistry with supporting quantitative instruments for the real-time analysis of medical diagnostic markers, pathogens and bio-warfare agents.
In June 2002, the Company introduced its first commercial product line, OptArray™ micro array slides. The OptArray™ slides feature a proprietary, patented surface chemistry designed for oligonucleotide and protein micro-array applications. In August 2003, the Company introduced OptiPlate™, microtiter plates providing smaller arrays that can provide a validation format compatible with today's high throughput laboratory robotics. YoDX™ is an assay processing technology that eliminates several time consuming procedures resulting in an automated, high speed low cost method for assay processing. Finally, QuanDX™ is a quantitative digital detection technology that has the potential for ultra-sensitive analytical detection.
Having launched its first commercial research products and started to negotiate a licensing agreement with SCHOTT Nexterion for global manufacturing and distribution, the Company is now focusing its development resources on the BACcelr8r™ diagnostic platform. The new platform will integrate QuanDx™ and YoDx™ instrumentation with disposable assay chips that use OptiChem™ coatings. The Company intends to launch a commercial BACcelr8r™ product for rapid bacterial pathogen diagnostics.
Before making an investment in this security, we advice that you seek consultation with a qualified investment professional. Please read the disclaimer printed in this page.
OptiChem™
OptiChem™, the Company's proprietary, high performance
surface chemistry has unique properties to increase sensitivity, specificity and improve assay reproducibility. OptiChem™ surface chemistry reduces the cleanup requirements for assays while still reducing the interference as compared to competing surfaces.
OptArray™ and OptiPlate™
OptArray™ slides feature a proprietary coating on specially selected micro-array glass. OptArray™ slides, featuring OptiChem™, offer low non-specific binding, high probe capacity and low fluorescence with exceptional signal to noise ratio and covalent probe immobilization. OptiPlate™ micro-arraying plates contain the same OptiChem™ surface chemistry as OptArray™. OptiPlate™ also contain similar glass that is mounted onto a high-quality 96 and 384 well microtiter frame for use with high throughput robotics.
QuanDX™
QuanDX™ is a proprietary digital detection technology with the potential for improved sensitivity over existing detection platforms used in assay processing. QuanDX™ uses a unique method to eliminate interference in a sample.
YoDx™
YoDx™ instrumentation provides rapid assay processing using a proprietary concentration method.
BACcelr8r™
The BACcelr8r™ will be an integrated instrumentation system, using QuanDx™ and YoDx™ technologies, and disposable analytical chips coated with OptiChem™.
|
|
In the News
March 16, 2004 - The Company released its Quarterly Report for the period ended January 31, 2004. In the news release, Chief Executive Officer Thomas Geimer stated that the Company advanced the development of BACcelr8r™, an analytical system that will integrate our three existing technologies - OptiChem™, QuanDx™, and YoDx™. Mr. Geimer also stated that the Company continues to commercialize OptiChem™ through two product lines, OptArray™ and OptiPlate™, both of which employ OptiChem's proprietary coatings to provide high-density DNA micro-arrays.
|
|
About Us
Accelr8 Technology Corporation is focused on the development of a proprietary surface chemistry platform with supporting quantitative instruments for the real-time analysis of medical diagnostic markers, pathogens and bio-warfare agents.
Key Points
- Revolutionary surface chemistry technology platform
- Significant cash position
- Excellent management team
- Platform technology applicable to multiple industries
- Operating company with revenues and cash flow
|
|
|
Key Information
|
|
Current Stock Price
|
$2.45
|
|
52 Week Low
|
$0.97
|
|
52 Week High
|
$6.95
|
|
Stock Symbol
|
AXK
|
|
Exchange
|
ASE
|
|
Shares Outstanding
|
9,961,210
|
Management
|
|
Thomas V. Geimer |
CEO, CFO, SEC |
|
David Howson |
President |
|
Charles E. Gerretson |
Director |
|
A. Alexander Arnold III |
Director
|
Michael J. Lochhead, Ph.D. |
Senior Scientist |
|
Charles Greef, Ph.D. |
Senior Scientist |
|
Steven W. Metzger |
Scientist |
|
David W. Grainger, Ph.D. |
Chmn. Sc. Adv. Comm. |
|
David Goldberg, Ph.D. |
Consultant
|
Headquarters:
Accelr8 Technology Corporation
303 East 17th Avenue, Suite 108
Denver, CO 80203
(P) (303) 863-8088
(F) (303) 863-1218
Website: www.accelr8.com
All dollar figures are in U.S. dollars. To obtain copies, please contact Kenneth Maciora at Empire Relations Group Inc. at (516)750-9719.
Download/Print PDF
of this Gold Star Report
| |
|
Disclaimer
This Gold Star Report™ contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties, and other factors, not under the Company's control, which may cause actual results, performance, or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward looking statements. This Profile is prepared for general information only. It does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this profile. The information and statistical data contained within have been obtained from sources believed to be reliable but in no way are warranted as to accuracy or completeness. This is not a solicitation of any offer to buy or sell. Empire Relations Group Inc., its affiliates, directors, officers, employees and employee benefit programs do not maintain an equity position, either long or short, in this security at this time. Empire Relations Group Inc. has not received any compensation for the production of this Gold Star Report Copyright © 2004. Empire Relations Group Inc. All rights reserved.
|
|
Gold Star Report
|
|
|
|
|
